Cartilage+OA Flashcards

1
Q

What fraction of people above 45yrs seek treatment for OA?

A

1/3
-81% of these have constant pain or functional limitations
-7.5 million working days lost per year in UK
-OA pain is the commonest reason for joint replacement
-USA: predicted 0.5M hip replacements each year by 2030

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the commonest reason for joint replacement?

A

OA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is shown in this arthroscopy?

A

A chondral defect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What components make up the cartilage ECM and what are 2 of their functions?

A

Aggrecan(type of proteoglycan)-Resist compression
T2 collagens-High tensile strength
Water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Outline the function of the chondrocyte

A

<5% tissue
Producer and degrader of the cartilage matrix
Highly metabolically active
Exist in relative hypoxia
Interactions with matrix: growth factors, mechano-transduction
No cell division after adolescence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Give the 4 layers of hyaline cartilage including the location of the tide mark

A

Superficial layer
Transitional/Intermediate
Deep/Radial
(Tide mark)
Calcified
——-Bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What type of enzyme breaks down collagen?

A

Collagenases-A type of metalloproteinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which metalloproteinase are useful for breaking down collagen?

A

MMPs-3,11,18

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What type of molecule is MMP-3?

A

A stromelysin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Outline the structure of aggrecan

A

Sugar chains off of a protein backbone, attached to hyaluronan, contains 3 major domains
-Branches of keratin sulphate and chondroitin sulphate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Where can aggrecan be cleaved and by what?

A

Matrix metalloproteinases between amino acids 341-342

Aggrecanases between amino acids 373-374

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the intrinsic anabolic/anti-catabolic factors for articular cartilage?

A

TIMPs (Tissue Inhibitor of Metalloproteinases) 1-4
Growth factors e.g. fibroblast growth factor (FGF-2), Insulin-like growth factor (IGF), Transforming growth factor (TGF)-β, activin A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the extrinsic anabolic/anti-catabolic factors for articular cartilage?

A

Hormones e.g. testosterone, estrogen
Some drugs e.g. FGF-18

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Simply, why does cartilage matrix loss occur?

A

Excessive degradation compared to repair

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What part of your knee supports most of the weight?

A

The medial compartment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What occurs if your joints are absent of mechanical load?

A

You can’t maintain cartilage thickness and turnover, leading to cartilage atrophy

17
Q

How much more load is there through the tibiofemoral joint of the knee compared to standing with:
Walking
Jumping
Running
Climbing stairs

A

Walking – 2-6 X body weight
Jumping – 7-9 X body weight
Running – 3-8 X body weight
Climbing stairs – 3-10 X body weight

18
Q

Describe the pathogenesis of OA

A

Inflammation
Repair/remodelling of the cartilage
Pain

19
Q

What occurs to the matrix components of cartilage in OA pathology

A

Proteoglycan-Fragmented by aggrecanases
Water-Increased by initial swelling, then lost
Collagen-Broken down by collagenases

20
Q

Describe the pathology of EARLY OA

A

-Loss of proteoglycans
-Fibrillation of tissues

21
Q

Features of established OA that early OA doesn’t have?

A

Established has:
-Fissuring
-Partial/full thickness cartilage loss
-Osteophytes, bone cysts, synovial inflammation

22
Q

What are the risk factors for OA?

A

Age
Obesity
Mechanicals:Joint injury, joint misalignment
Genetics
Chondrodysplasias(e.g stickler syndrome)
Secondary joint damage due to inflammatory arthropathies e.g. rheumatoid arthritis

23
Q

What percent of meniscal/ACL tear victims will develop OA in the next 5-10 years

24
Q

Give some evidence for mechanical factors influencing the development of OA

A

Destabilising joint injuries increase risk of OA
Intra-articular fracture increases the risk of OA

25
Why does lack of aggrecanase stop the loss of cartilage after joint injury?
Cartilage is a biologically active process, dependent on aggrecanases
26
Outline the 2 pathways that lead to symptomatic OA
Abnormal joint + Normal load Normal joint + Abnormal load Leads to mechanical injury, leading to incorrect remodelling of cartilage Then symptomatic OA
27
Do all OA cases progress?
No, some can remain at the same severity, or even remise
28
Demographically with age and sex where is OA more prevalent?
With greater age and more in women
29
Why are OA rates increasing?
Higher obesity levels, poorer diets that aren't equipped to maintain cartilage health
30
How is OA diagnosed?
Clinically: Stiffness Pain on function Crepitus, bony deformity X-ray: Osteophytes Joint space narrowing Bone cysts Blood tests: Normal CRP Negative tests for RA Other tests to exclude secondary causes
31
What are these?
Heberdens' nodes, diagnostic of hand OA
32
Give 3 surgical options for OA treatment
**Total joint replacement** /‘arthroplasty’(hip or knee) is a highly effective treatment (best results when pain high, function poor, over 60, end stage radiographic disease) **Uni-compartmental replacement** for the knee is possible **Trapeziectomy** (removal of a thumb bone) is a good surgical treatment for base of thumb OA
33
Outline 2 new drugs targeted at treating OA and their effects
SyMOADs(Symptom modifying OA drug)-Treat pain+Improve function DMOADs(Disease modifying OA drug)-Prevent/Slow early onset of OA
34
What are 3 requirements for clinical trials of new OA drugs
-Find drugs targeting the right sites -Using the right population(Subgrouping+) -Using the right outcome measurements(Imaging+patient reported outcomes)